{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:30Z","timestamp":1786979610478,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Die Verbreitung multiresistenter Erreger (MRE) stellt ein globales Problem dar, welches die \u00f6ffentliche Gesundheit und die Wirtschaft vor signifikante Herausforderungen stellt. Prognostizierte Entwicklungen lassen den Schluss zu, dass die Zahl der MRE-assoziierten Todesf\u00e4lle bis 2050 global signifikant ansteigen wird. In etwa 6\u202f% der nosokomialen Infektionen in Deutschland sind MRE involviert, was einer Anzahl von 24.000 bis 36.000 MRE-Infektionen pro Jahr entspricht. Zusammen mit den ambulant erworbenen Infektionen durch MRE sind es j\u00e4hrlich etwa 54.500 Infektionen. In Deutschland wird die Zahl der unmittelbar MRE-bedingten Todesf\u00e4lle auf 9700 pro Jahr gesch\u00e4tzt. F\u00fcr die Zukunft ist in der station\u00e4ren Versorgung vor allem mit einer signifikanten Zunahme der Carbapenem-resistenten Isolate von\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    und\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    zu rechnen. Eine \u00fcberschlagm\u00e4\u00dfige Absch\u00e4tzung der gesamtwirtschaftlichen Mehrkosten einer MRE-Infektion bei station\u00e4rer Behandlung in Deutschland ergibt eine H\u00f6he von ca.\u00a027.000\u202f\u20ac. Unter Ber\u00fccksichtigung der wirtschaftlichen Konsequenzen entspricht dies auf Deutschland hochgerechnet einem j\u00e4hrlichen Betrag von ca. 4\u202fMrd.\u202f\u20ac. Die genannten Daten basieren in der Regel auf Sch\u00e4tzungen. Um auch Kostenbereiche wie Aufwendungen f\u00fcr die Rehabilitation sowie die Folgen des gro\u00dffl\u00e4chigen Antibiotikaeinsatzes in der Tierhaltung ad\u00e4quat ber\u00fccksichtigen zu k\u00f6nnen, besteht erheblicher Forschungsbedarf. Um die Effektivit\u00e4t k\u00fcnftiger Ma\u00dfnahmen zur Pr\u00e4vention und Eind\u00e4mmung von Multiresistenzen ad\u00e4quat evaluieren zu k\u00f6nnen, sind mehr valide Daten unerl\u00e4sslich.\n                  <\/jats:p>","DOI":"10.1007\/s00103-025-04061-1","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:00:37Z","timestamp":1746680437000},"page":"584-592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gesundheits\u00f6konomische Bedeutung antimikrobieller Resistenzen","Health economic significance of antimicrobial resistance"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-3384","authenticated-orcid":false,"given":"Christian","family":"Willy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-9760","authenticated-orcid":false,"given":"Felix","family":"Br\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"4061_CR1","unstructured":"OECD (2019) Antimicrobial resistance\u2014tackling the burden in the European Union. https:\/\/www.oecd.org\/en\/publications\/antimicrobial-resistance-tackling-the-burden-in-the-european-union_33cbfc1c-en.html. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/ebnurs-2022-103540:10.1136\/ebnurs-2022-103540","author":"R Ranjbar","year":"2023","unstructured":"Ranjbar\u00a0R, Alam\u00a0M (2023) Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a\u00a0systematic analysis. Evid Based Nurs. https:\/\/doi.org\/10.1136\/ebnurs-2022-103540:10.1136\/ebnurs-2022-103540","journal-title":"Evid Based Nurs"},{"key":"4061_CR3","unstructured":"ECDC (2023) Antimikrobielle Resistenz: Wie k\u00f6nnen die Ziele bis 2030 erreicht werden? https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AMR%20brief%20-%20EAAD%202023_DE.pdf. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"GBDAR Collaborators","year":"2024","unstructured":"Collaborators\u00a0GBDAR (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a\u00a0systematic analysis with forecasts to 2050. Lancet 404:1199\u20131226. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1","journal-title":"Lancet"},{"key":"4061_CR5","unstructured":"O\u2019Neill J (2016) Tackling drug-resistant infections globally: final report and recommendations. The Review On Antimicrobial Resistance. https:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance C","year":"2022","unstructured":"Antimicrobial Resistance C (2022) Global burden of bacterial antimicrobial resistance in 2019: a\u00a0systematic analysis. Lancet 399:629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"4061_CR7","unstructured":"O\u2019Neill J (2014) Review on antimicrobial resistance. Antimicrobial resistance: tackling a\u00a0crisis for the health and wealth of nations. 2014. AMR review paper. https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR8","unstructured":"OECD (2018) Stemming the superbug tide-Just a\u00a0few dollars more. https:\/\/www.oecd.org\/en\/publications\/stemming-the-superbug-tide_9789264307599-en.html. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3238\/arztebl.2017.0851","volume":"114","author":"M Behnke","year":"2017","unstructured":"Behnke\u00a0M, Aghdassi\u00a0SJ, Hansen\u00a0S, Diaz\u00a0LAP, Gastmeier\u00a0P, Piening\u00a0B (2017) The prevalence of nosocomial infection and antibiotic use in German hospitals. Dtsch \u00c4rztebl Int 114:851\u2013857. https:\/\/doi.org\/10.3238\/arztebl.2017.0851","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"4061_CR10","unstructured":"(2018) Deutsche Nationale Punkt-Pr\u00e4valenzstudie zu nosokomialen Infektionen und Antibiotika-Anwendung 2011 \u2013 Abschlussbericht. https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/5_Publikationen\/Gesundheit\/Berichte\/Abschlussbericht_Deutsche_Nationale_Punkt-Praevalenzstudie__zu_nosokomialen_Infektionen_und_Antibiotika-Anwendung_2011.pdf. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ijmm.2015.08.034","volume":"305","author":"C Schroder","year":"2015","unstructured":"Schroder\u00a0C, Schwab\u00a0F, Behnke\u00a0M et\u00a0al (2015) Epidemiology of healthcare associated infections in Germany: nearly 20\u00a0years of surveillance. Int J Med Microbiol 305:799\u2013806. https:\/\/doi.org\/10.1016\/j.ijmm.2015.08.034","journal-title":"Int J Med Microbiol"},{"key":"4061_CR12","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.46.1900135","author":"B Zacher","year":"2019","unstructured":"Zacher\u00a0B, Haller\u00a0S, Willrich\u00a0N et\u00a0al (2019) Application of a\u00a0new methodology and R package reveals a\u00a0high burden of healthcare-associated infections (HAI) in Germany compared to the average in the European Union\/European Economic Area, 2011 to 2012. Euro Surveill. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.46.1900135","journal-title":"Euro Surveill"},{"key":"4061_CR13","unstructured":"NRZ (2023) Deutsche nationale Punkt-Pr\u00e4valenzerhebung zu nosokomialen Infektionen und Antibiotika-Anwendung 2022 \u2013 Abschlussbericht. https:\/\/www.nrz-hygiene.de\/files\/Projekte\/PPS%202022\/PPS_2022_Abschlussbericht_Final_Upload.pdf. Zugegriffen: 18. M\u00e4rz 2025"},{"issue":"06","key":"4061_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1055\/s-0041-106299","volume":"141","author":"P Gastmeier","year":"2016","unstructured":"Gastmeier\u00a0P, Geffers\u00a0C, Herrmann\u00a0M et\u00a0al (2016) Nosocomial infections and infections with multidrug-resistant pathogens\u2014frequency and mortality. Dtsch Med Wochenschr 141(06):421\u2013426. https:\/\/doi.org\/10.1055\/s-0041-106299","journal-title":"Dtsch Med Wochenschr"},{"key":"4061_CR15","unstructured":"Willy C, Br\u00f6cker F (2023) Phage2030\u2014Introducing phage therapy in Germany by 2030. https:\/\/cms.system.sprind.org\/uploads\/Summary_Phage2030_0ebf7be2bf.pdf. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini\u00a0A, Hogberg\u00a0LD, Plachouras\u00a0D et\u00a0al (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a\u00a0population-level modelling analysis. Lancet Infect Dis 19:56\u201366. https:\/\/doi.org\/10.1016\/S1473-3099(18)30605-4","journal-title":"Lancet Infect Dis"},{"key":"4061_CR17","unstructured":"RKI (2022) Antibiotikaresistenzen, eine schleichende Pandemie: Einweihung des WHO-Kooperationszentrums f\u00fcr Antibiotikaresistenz am RKI. Pressemitteilung des Robert Koch-Instituts (18.10.2022). https:\/\/www.rki.de\/DE\/Aktuelles\/Neuigkeiten-und-Presse\/Pressemitteilungen\/2022\/06_2022.html?templateQueryString=pressemitteilung+06+2022. Zugegriffen: 27. M\u00e4rz 2025"},{"key":"4061_CR18","unstructured":"Bundesgesundheitsministerium (2022) The burden of antimicrobial resistance in G7 countries and globally: an urgent call for action. https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/A\/Antibiotika-Resistenz-Strategie\/AMR_Brochure_-_G7_Summit.pdf. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13756-019-0594-3","volume":"8","author":"R Markwart","year":"2019","unstructured":"Markwart\u00a0R, Willrich\u00a0N, Haller\u00a0S et\u00a0al (2019) The rise in vancomycin-resistant Enterococcus faecium in Germany: data from the German Antimicrobial Resistance Surveillance (ARS). Antimicrob Resist Infect Control 8:147. https:\/\/doi.org\/10.1186\/s13756-019-0594-3","journal-title":"Antimicrob Resist Infect Control"},{"key":"4061_CR20","unstructured":"RKI Neue Daten aus der Antibiotika-Resistenz-Surveillance (ARS) und der Antibiotika-Verbrauchs-Surveillance (AVS) des Robert Koch-Instituts. https:\/\/www.rki.de\/DE\/Content\/Infekt\/Antibiotikaresistenz\/RKI-Aktivitaeten\/ARS_AVS.html (Erstellt: 22. Sept. 2023). Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR21","unstructured":"RKI H\u00e4ufigkeit, Eigenschaften und Verbreitung von MRSA in Deutschland \u2013 Zur Situation 2021\/2022. Infektionsschutz \u2013 Epidemiologisches Bulletin (44\/2023). https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/Epidemiologisches-Bulletin\/2023\/44_23.pdf?__blob=publicationFile&v=1 (Erstellt: 2. Nov. 2023). Zugegriffen: 24. M\u00e4rz 2025"},{"key":"4061_CR22","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200926","author":"M Sandfort","year":"2022","unstructured":"Sandfort\u00a0M, Hans\u00a0JB, Fischer\u00a0MA et\u00a0al (2022) Increase in NDM\u20111 and NDM-1\/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022. Euro Surveill. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.50.2200926","journal-title":"Euro Surveill"},{"key":"4061_CR23","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.20.2200672","author":"M Rodenbeck","year":"2023","unstructured":"Rodenbeck\u00a0M, Ayobami\u00a0O, Eckmanns\u00a0T, Pletz\u00a0MW, Bleidorn\u00a0J, Markwart\u00a0R (2023) Clinical epidemiology and case fatality due to antimicrobial resistance in Germany: a\u00a0systematic review and meta-analysis, 1\u00a0January 2010 to 31\u00a0December 2021. Euro Surveill. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.20.2200672","journal-title":"Euro Surveill"},{"key":"4061_CR24","doi-asserted-by":"publisher","first-page":"e70008","DOI":"10.1111\/1758-2229.70008","volume":"16","author":"M Fernandez Salgueiro","year":"2024","unstructured":"Fernandez Salgueiro\u00a0M, Cernuda Martinez\u00a0JA, Gan\u00a0RK, Arcos Gonzalez\u00a0P (2024) Climate change and antibiotic resistance: a\u00a0scoping review. Environ Microbiol Rep 16:e70008. https:\/\/doi.org\/10.1111\/1758-2229.70008","journal-title":"Environ Microbiol Rep"},{"key":"4061_CR25","doi-asserted-by":"publisher","first-page":"642983","DOI":"10.3389\/fpubh.2021.642983","volume":"9","author":"M Elisabeth","year":"2021","unstructured":"Elisabeth\u00a0M, Maneesh\u00a0PS, Katarina\u00a0SF, Slobodan\u00a0Z, Michael\u00a0S (2021) Antimicrobial resistance & migrants in Sweden: poor living conditions enforced by migration control policies as a\u00a0risk factor for optimal public health management. Front Public Health 9:642983. https:\/\/doi.org\/10.3389\/fpubh.2021.642983","journal-title":"Front Public Health"},{"key":"4061_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5334\/aogh.4628","volume":"91","author":"S Cotugno","year":"2025","unstructured":"Cotugno\u00a0S, De Vita\u00a0E, Frallonardo\u00a0L et\u00a0al (2025) Antimicrobial resistance and migration: interrelation between two hot topics in global health. Ann Glob Health 91:12. https:\/\/doi.org\/10.5334\/aogh.4628","journal-title":"Ann Glob Health"},{"key":"4061_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.cmi.2024.03.029","volume":"30","author":"G Granata","year":"2024","unstructured":"Granata\u00a0G, Petersen\u00a0E, Capone\u00a0A et\u00a0al (2024) The impact of armed conflict on the development and global spread of antibiotic resistance: a\u00a0systematic review. Clin Microbiol Infect 30:858\u2013865. https:\/\/doi.org\/10.1016\/j.cmi.2024.03.029","journal-title":"Clin Microbiol Infect"},{"key":"4061_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1473-3099(16)30319-X","volume":"17","author":"MS Arcilla","year":"2017","unstructured":"Arcilla\u00a0MS, van Hattem\u00a0JM, Haverkate\u00a0MR et\u00a0al (2017) Import and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a\u00a0prospective, multicentre cohort study. Lancet Infect Dis 17:78\u201385. https:\/\/doi.org\/10.1016\/S1473-3099(16)30319-X","journal-title":"Lancet Infect Dis"},{"key":"4061_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23040795","author":"C Manyi-Loh","year":"2018","unstructured":"Manyi-Loh\u00a0C, Mamphweli\u00a0S, Meyer\u00a0E, Okoh\u00a0A (2018) Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules. https:\/\/doi.org\/10.3390\/molecules23040795","journal-title":"Molecules"},{"key":"4061_CR30","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.2147\/IDR.S234610","volume":"12","author":"P Dadgostar","year":"2019","unstructured":"Dadgostar\u00a0P (2019) Antimicrobial resistance: implications and costs. Infect Drug Resist 12:3903\u20133910. https:\/\/doi.org\/10.2147\/IDR.S234610","journal-title":"Infect Drug Resist"},{"key":"4061_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13756-018-0336-y","volume":"7","author":"NR Naylor","year":"2018","unstructured":"Naylor\u00a0NR, Atun\u00a0R, Zhu\u00a0N et\u00a0al (2018) Estimating the burden of antimicrobial resistance: a\u00a0systematic literature review. Antimicrob Resist Infect Control 7:58. https:\/\/doi.org\/10.1186\/s13756-018-0336-y","journal-title":"Antimicrob Resist Infect Control"},{"key":"4061_CR32","unstructured":"Weltbank (2017) Drug-resistant infections a\u00a0threat to our economic future. https:\/\/documents1.worldbank.org\/curated\/en\/323311493396993758\/pdf\/final-report.pdf. Zugegriffen: 9. Febr. 2025"},{"key":"4061_CR33","first-page":"179","volume":"18","author":"E Utt","year":"2016","unstructured":"Utt\u00a0E, Wells\u00a0C (2016) The global response to the threat of antimicrobial resistance and the important role of vaccines. Pharm Policy Law 18:179\u2013197","journal-title":"Pharm Policy Law"},{"key":"4061_CR34","doi-asserted-by":"crossref","unstructured":"OECD (2023) Embracing a\u00a0one health framework to fight antimicrobial resistance. https:\/\/www.oecd.org\/en\/publications\/embracing-a-one-health-framework-to-fight-antimicrobial-resistance_ce44c755-en.html. Zugegriffen: 9. Febr. 2025","DOI":"10.1787\/ce44c755-en"},{"key":"4061_CR35","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1055\/s-0034-1387709","volume":"77","author":"H Oberdorfer","year":"2015","unstructured":"Oberdorfer\u00a0H, Hubner\u00a0C, Linder\u00a0R, Flessa\u00a0S (2015) Additional costs for care of patients with multi-resistant pathogens\u2014an analysis from the perspective of a\u00a0statutory health insurance. Gesundheitswesen 77:854\u2013860. https:\/\/doi.org\/10.1055\/s-0034-1387709","journal-title":"Gesundheitswesen"},{"key":"4061_CR36","unstructured":"\u00c4rztezeitung (2015) Jede MRE-Infektion bringt 17.500 Euro Mehrkosten. https:\/\/www.aerztezeitung.de\/Politik\/Jede-MRE-Infektion-bringt-17500-Euro-Mehrkosten-235307.html. Zugegriffen: 9. Febr. 2025 (TK-Studie)"},{"key":"4061_CR37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1086\/502274","volume":"24","author":"CE Herr","year":"2003","unstructured":"Herr\u00a0CE, Heckrodt\u00a0TH, Hofmann\u00a0FA, Schnettler\u00a0R, Eikmann\u00a0TF (2003) Additional costs for preventing the spread of methicillin-resistant Staphylococcus aureus and a\u00a0strategy for reducing these costs on a\u00a0surgical ward. Infect Control Hosp Epidemiol 24:673\u2013678. https:\/\/doi.org\/10.1086\/502274","journal-title":"Infect Control Hosp Epidemiol"},{"key":"4061_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1469-0691.2005.01153.x","volume":"11","author":"MH Wernitz","year":"2005","unstructured":"Wernitz\u00a0MH, Keck\u00a0S, Swidsinski\u00a0S, Schulz\u00a0S, Veit\u00a0SK (2005) Cost analysis of a\u00a0hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 11:466\u2013471. https:\/\/doi.org\/10.1111\/j.1469-0691.2005.01153.x","journal-title":"Clin Microbiol Infect"},{"key":"4061_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-017-0291-z","volume":"7","author":"L Puchter","year":"2018","unstructured":"Puchter\u00a0L, Chaberny\u00a0IF, Schwab\u00a0F, Vonberg\u00a0RP, Bange\u00a0FC, Ebadi\u00a0E (2018) Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control 7:1. https:\/\/doi.org\/10.1186\/s13756-017-0291-z","journal-title":"Antimicrob Resist Infect Control"},{"key":"4061_CR40","doi-asserted-by":"publisher","first-page":"e008458","DOI":"10.1136\/bmjopen-2015-008458","volume":"6","author":"C Huebner","year":"2016","unstructured":"Huebner\u00a0C, Roggelin\u00a0M, Flessa\u00a0S (2016) Economic burden of multidrug-resistant bacteria in nursing homes in Germany: a\u00a0cost analysis based on empirical data. BMJ Open 6:e8458. https:\/\/doi.org\/10.1136\/bmjopen-2015-008458","journal-title":"BMJ Open"},{"key":"4061_CR41","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1073\/pnas.1503141112","volume":"112","author":"TP Van Boeckel","year":"2015","unstructured":"Van Boeckel\u00a0TP, Brower\u00a0C, Gilbert\u00a0M et\u00a0al (2015) Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S\u00a0A 112:5649\u20135654. https:\/\/doi.org\/10.1073\/pnas.1503141112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4061_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s43016-023-00713-0","volume":"4","author":"J Gil","year":"2023","unstructured":"Gil\u00a0J (2023) Antimicrobial use in livestock farming. Nat Food 4:138\u2013138. https:\/\/doi.org\/10.1038\/s43016-023-00713-0","journal-title":"Nat Food"},{"key":"4061_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081075","author":"AA Moawad","year":"2022","unstructured":"Moawad\u00a0AA, Hotzel\u00a0H, Hafez\u00a0HM et\u00a0al (2022) Occurrence, phenotypic and molecular characteristics of extended-spectrum beta-lactamase-producing escherichia coli in healthy Turkeys in northern Egypt. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11081075","journal-title":"Antibiotics"},{"key":"4061_CR44","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2016.4565","author":"A Allende","year":"2016","unstructured":"Allende\u00a0A, Bolton\u00a0DJ, Chemaly\u00a0M et\u00a0al (2016) Evaluation of the safety and efficacy of Listex\u2122 P100 for reduction of pathogens on different ready-to-eat (RTE) food products. EFS2. https:\/\/doi.org\/10.2903\/j.efsa.2016.4565","journal-title":"EFS2"},{"key":"4061_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40258-022-00728-x","volume":"20","author":"NT Hillock","year":"2022","unstructured":"Hillock\u00a0NT, Merlin\u00a0TL, Turnidge\u00a0J, Karnon\u00a0J (2022) Modelling the future clinical and economic burden of antimicrobial resistance: the feasibility and value of models to inform policy. Appl Health Econ Health Policy 20:479\u2013486. https:\/\/doi.org\/10.1007\/s40258-022-00728-x","journal-title":"Appl Health Econ Health Policy"},{"key":"4061_CR46","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1086\/323758","volume":"33","author":"D Howard","year":"2001","unstructured":"Howard\u00a0D, Cordell\u00a0R, McGowan\u00a0JE Jr. et\u00a0al (2001) Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop. Clin Infect Dis 33:1573\u20131578. https:\/\/doi.org\/10.1086\/323758","journal-title":"Clin Infect Dis"},{"key":"4061_CR47","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ijantimicag.2004.09.009","volume":"24","author":"DL Monnet","year":"2004","unstructured":"Monnet\u00a0DL, Frimodt-Moller\u00a0N (2004) Only percentage within species; neither incidence, nor prevalence: demographic information and representative surveillance data are urgently needed to estimate the burden of antimicrobial resistance. Int J Antimicrob Agents 24:622\u2013623 (author reply 623\u2013624.https:\/\/doi.org\/10.1016\/j.ijantimicag.2004.09.009)","journal-title":"Int J Antimicrob Agents"},{"key":"4061_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13643-016-0364-8","volume":"5","author":"NR Naylor","year":"2016","unstructured":"Naylor\u00a0NR, Silva\u00a0S, Kulasabanathan\u00a0K et\u00a0al (2016) Methods for estimating the burden of antimicrobial resistance: a\u00a0systematic literature review protocol. Syst Rev 5:187. https:\/\/doi.org\/10.1186\/s13643-016-0364-8","journal-title":"Syst Rev"},{"key":"4061_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jped.2015.06.001","volume":"91","author":"M Sharland","year":"2015","unstructured":"Sharland\u00a0M, Saroey\u00a0P, Berezin\u00a0EN (2015) The global threat of antimicrobial resistance\u2014The need for standardized surveillance tools to define burden and develop interventions. J\u00a0Pediatr 91:410\u2013412. https:\/\/doi.org\/10.1016\/j.jped.2015.06.001","journal-title":"J Pediatr"},{"key":"4061_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13756-018-0379-0","volume":"7","author":"TM Wozniak","year":"2018","unstructured":"Wozniak\u00a0TM (2018) Letter to the editor in response to estimating the burden of antimicrobial resistance: a\u00a0systematic literature review. Antimicrob Resist Infect Control 7:91. https:\/\/doi.org\/10.1186\/s13756-018-0379-0","journal-title":"Antimicrob Resist Infect Control"},{"key":"4061_CR51","first-page":"345","volume":"27","author":"T Heinen-Kammerer","year":"2006","unstructured":"Heinen-Kammerer\u00a0T, Karig\u00a0I, Irrgang\u00a0V, Rychlik\u00a0R (2006) Pr\u00e4valenz, Krankheitslast und -kosten multiresistenter Erreger in Deutschland. Krankenhauspharmazie 27:345\u2013350","journal-title":"Krankenhauspharmazie"},{"key":"4061_CR52","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s10096-012-1632-8","volume":"31","author":"A Tubbicke","year":"2012","unstructured":"Tubbicke\u00a0A, Hubner\u00a0C, Kramer\u00a0A, Hubner\u00a0NO, Flessa\u00a0S (2012) Transmission rates, screening methods and costs of MRSA\u2014a systematic literature review related to the prevalence in Germany. Eur J Clin Microbiol Infect Dis 31:2497\u20132511. https:\/\/doi.org\/10.1007\/s10096-012-1632-8","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4061_CR53","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s10096-014-2131-x","volume":"33","author":"C Hubner","year":"2014","unstructured":"Hubner\u00a0C, Hubner\u00a0NO, Hopert\u00a0K, Maletzki\u00a0S, Flessa\u00a0S (2014) Analysis of MRSA-attributed costs of hospitalized patients in Germany. Eur J Clin Microbiol Infect Dis 33:1817\u20131822. https:\/\/doi.org\/10.1007\/s10096-014-2131-x","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-025-04061-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-025-04061-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-025-04061-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T10:26:44Z","timestamp":1748860004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-025-04061-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4061"],"URL":"https:\/\/doi.org\/10.1007\/s00103-025-04061-1","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Willy und F.\u00a0Br\u00f6cker geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}